Timing of cyclosporin-A therapy for abrogation of HVG and GVH responses in rats.
Treatment with cyclosporin A was most effective in abrogating popliteal-lymph-node enlargement induced by host-versus-graft and graft-versus-host reactivity in rats when started before injection of donor-strain lymphocytes. Popliteal lymph-node enlargement was never completely abolished, and splenic lymphocytes from recipients treated with cyclosporin A showed no significant reduction in their response to donor-strain lymphocytes in mixed lymphocyte cultures, suggesting that clonal deletion had not taken place. Mixed lymphocyte cultures also indicated that cyclosporin treatment had not reduced the antigenicity of recipient lymphocytes towards donor strain.
D000818:Animals; D005260:Female; D005656:Fungal Proteins / Q000008:administration & dosage; D006087:Graft vs Host Reaction / Q000187:drug effects*; D006789:Host vs Graft Reaction / Q000187:drug effects*; D006984:Hypertrophy / Q000517:prevention & control; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D066298:In Vitro Techniques; D007717:Knee; D008198:Lymph Nodes / Q000276:immunology / Q000473:pathology; D007959:Lymphocyte Culture Test, Mixed; D017710:Lymphocyte Transfusion; D008297:Male; D010456:Peptides, Cyclic / Q000008:administration & dosage*; D051381:Rats; D013154:Spleen / Q000166:cytology; D013997:Time Factors; D014184:Transplantation, Homologous
D005656:Fungal Proteins; D007166:Immunosuppressive Agents; D010456:Peptides, Cyclic